| Overview |
| bs-6864R-FITC |
| NALP12 Polyclonal Antibody, FITC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NALP12 |
| 176-270/1061 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 91662 |
| Cytoplasm |
| CLR19.3; FCAS2; Monarch 1; Monarch-1; NACHT, leucine rich repeat and PYD containing 12; NACHT, LRR and PYD containing protein 12; NACHT, LRR and PYD domains-containing protein 12; NAL12_HUMAN; NLR family, pyrin domain containing 12; NLRP12; Nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 12; PAN6; PYPAF7; PYRIN containing APAF1 like protein 7; PYRIN-containing APAF1-like protein 7; Regulated by nitric oxide; RNO; RNO2. |
| May mediate activation of CASP1 via ASC and promote activation of NF-kappa-B via IKK.NALP proteins are cytoplasmic proteins that form a subfamily within the larger CATERPILLER family and are thought to play a crucial role in cell proliferation and reproduction. Like all other NALP family members, NALP12, also known as Monarch-1, has a C-terminal leucine-rich repeat (LRR) region, an N-terminal Pyrin domain (PYD) followed by a NACHT domain, and a NACHT-associated domain. NALP12 is thought to act as an attenuating factor of inflammation by suppressing inflammatory responses such as NF-kB activation by TLR-signaling molecules MyD88, IRAK-1, TRAF6 and RIPK1 in activated monocytes. Recent evidence suggests that mutations in NALP12 result in hereditary periodic fever syndromes. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz